Immuron (Immuron) Asset Impairment Charge : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Immuron Asset Impairment Charge?

Immuron's Asset Impairment Charge for the six months ended in Dec. 2023 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Immuron Asset Impairment Charge Historical Data

The historical data trend for Immuron's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron Asset Impairment Charge Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Asset Impairment Charge

Get a 7-Day Free Trial

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Asset Impairment Charge	Get a 7-Day Free Trial												-	-	-	-	-

Immuron Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

Immuron Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Immuron's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (Immuron) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (NAS:IMRN) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

ANWA:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.